Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues

DOI: 10.1021/jm0310885
Journal of Medicinal Chemistry, 2004, 47, 1760-6.

#	Paper	IF	Citations
82	Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. *Journal of Neural Transmission*, **2004**, 111, 1455-71	4.3	107
81	Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. *Journal of Medicinal Chemistry*, **2004**, 47, 1767-74	8.3	171
80	Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 6212-7	3.4	110
79	Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 4438-46	2.9	45
78	Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. *Journal of Neurochemistry*, **2005**, 95, 68-78	6	177
77	Synthesis of novel N-substituted imidazolecarboxylic acid hydrazides as monoamine oxidase inhibitors. *Il Farmaco*, **2005**, 60, 237-40		5
76	Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. *Journal of Biological Chemistry*, **2005**, 280, 15761-6	5.4	163
75	Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. *Journal of Medicinal Chemistry*, **2005**, 48, 8148-54	8.3	84
74	Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. *Journal of Clinical Pharmacology*, **2005**, 45, 878-94	2.9	113
73	A mechanism-based inactivator for histone demethylase LSD1. *Journal of the American Chemical Society*, **2006**, 128, 4536-7	16.4	131
72	Thermodynamics of buried water clusters at a protein-ligand binding interface. *Journal of Physical Chemistry B*, **2006**, 110, 1464-75	3.4	92
71	Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. *American Journal of Health-System Pharmacy*, **2006**, 63, 915-28	2.2	39
70	To Market, To Market 2005. *Annual Reports in Medicinal Chemistry*, **2006**, 439-477	1.6	16
69	Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. *American Journal of Geriatric Pharmacotherapy*, **2006**, 4, 330-46		70
68	The therapeutic potential of monoamine oxidase inhibitors. *Nature Reviews Neuroscience*, **2006**, 7, 295-309	33.5	988
67	Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. *Biochemistry*, **2007**, 46, 6892-902	3.2	79
66	Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. *Journal of Medicinal Chemistry*, **2007**, 50, 5848-52	8.3	387

65	Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 5198-206	3.4	20
64	Hydrodynamically coupled water in surface adsorbed amino acids as a tool to study hydrated peptides. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2007**, 1774, 138-45	4	8
63	Kinetic properties of recombinant MAO-A on incorporation into phospholipid nanodisks. *Journal of Neural Transmission*, **2007**, 114, 699-702	4.3	21
62	Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties. *Journal of Neural Transmission*, **2007**, 114, 725-32	4.3	20
61	Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B. *Journal of Medicinal Chemistry*, **2008**, 51, 8019-26	8.3	39
60	Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models. *European Journal of Medicinal Chemistry*, **2009**, 44, 3584-90	6.8	30
59	Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. *Biochemistry*, **2009**, 48, 4220-30	3.2	233
58	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 1388-95	3.4	36
57	Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat. *Neuropsychobiology*, **2010**, 62, 213-20	4	9
56	Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. *Journal of Clinical Pharmacology*, **2010**, 50, 1420-8	2.9	32
55	A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. *International Review of Neurobiology*, **2011**, 100, 191-215	4.4	31
54	Identification of multifunctional small molecule-based reversible monoamine oxidase inhibitors. *MedChemComm*, **2011**, 2, 1099	5	17
53	Steered molecular dynamics simulations reveal important mechanisms in reversible monoamine oxidase B inhibition. *Biochemistry*, **2011**, 50, 6441-54	3.2	19
52	Irreversible Inhibition of Monoamine Oxidase B by the Antiparkinsonian Medicines Rasagiline and Selegiline: A Computational Study. *European Journal of Organic Chemistry*, **2011**, 2011, 6419-6433	3.2	27
51	Chapter 18:Discovery of Multi-Target Agents for Neurological Diseases via Ligand Design. *RSC Drug Discovery Series*, **2012**, 290-315	0.6	3
50	Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease. *Journal of Medicinal Chemistry*, **2012**, 55, 8483-92	8.3	120
49	The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?. *Journal of Clinical Pharmacology*, **2012**, 52, 620-8	2.9	24
48	Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. *Journal of Neural Transmission*, **2012**, 119, 405-14	4.3	23

47	Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. *Journal of Neural Transmission*, **2013**, 120, 435-44	4.3	23
46	Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria. *Journal of Neural Transmission*, **2013**, 120, 1539-51	4.3	23
45	In silico identification of novel and selective monoamine oxidase B inhibitors. *Journal of Neural Transmission*, **2013**, 120, 853-8	4.3	8
44	Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor. *Journal of Neural Transmission*, **2013**, 120, 875-82	4.3	15
43	Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. *Expert Review of Neurotherapeutics*, **2013**, 13, 671-84	4.3	40
42	Enzyme Inhibition and Inactivation. **2014**, 207-274		1
41	Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus. *British Journal of Pharmacology*, **2014**, 171, 5636-49	8.6	6
40	Regio- and Enantioselective Organocascade Michael–Michael Reactions: Construction of Chiral Trisubstituted Indanes. *European Journal of Organic Chemistry*, **2014**, 2014, 2677-2681	3.2	10
39	Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease. *ChemBioChem*, **2014**, 15, 1591-1598	3.8	7
38	Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency. *Journal of Medicinal Chemistry*, **2014**, 57, 6679-703	8.3	61
37	Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B. *Evidence-based Complementary and Alternative Medicine*, **2015**, 2015, 852194	2.3	12
36	Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 770-8	3.4	24
35	Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 6486-96	3.4	61
34	Synthesis of a Parkinson's Disease Treatment Drug, the R,R-Tartrate Salt of R-Rasagiline: A Three Week Introductory Organic Chemistry Lab Sequence. *Journal of Chemical Education*, **2016**, 93, 937-940	2.4	2
33	4-Organoseleno-Isoquinolines Selectively and Reversibly Inhibit the Cerebral Monoamine Oxidase B Activity. *Journal of Molecular Neuroscience*, **2016**, 59, 135-45	3.3	11
32	Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease. *Neuropharmacology*, **2016**, 109, 376-385	5.5	22
31	Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. *Journal of Neural Transmission*, **2016**, 123, 91-106	4.3	52
30	Molecular aspects of monoamine oxidase B. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2016**, 69, 81-9	5.5	45

29	Drugs related to monoamine oxidase activity. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2016**, 69, 112-24	5.5	46
28	Flavins as Covalent Catalysts: New Mechanisms Emerge. *Trends in Biochemical Sciences*, **2017**, 42, 457-469	10.3	81
27	Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease. *Future Medicinal Chemistry*, **2017**, 9, 811-832	4.1	35
26	Enantioselective bioreduction of benzo-fused cyclic ketones with engineered Candida glabrata ketoreductase 1 - a promising synthetic route to ladostigil (TV3326). *Organic and Biomolecular Chemistry*, **2017**, 15, 7374-7379	3.9	4
25	In vitro monoamine oxidase A and B inhibitory activity and molecular docking simulations of fucoxanthin. *Fisheries Science*, **2017**, 83, 123-132	1.9	16
24	Kinetics, mechanism, and inhibition of monoamine oxidase. *Journal of Neural Transmission*, **2018**, 125, 1659-1683	4.3	42
23	Privileged scaffolds as MAO inhibitors: Retrospect and prospects. *European Journal of Medicinal Chemistry*, **2018**, 145, 445-497	6.8	84
22	HPLC-UV assays for evaluation of inhibitors of mono and diamine oxidases using novel phenyltetrazolylalkanamine substrates. *Analytical Biochemistry*, **2018**, 549, 29-38	3.1	4
21	Evidence for a Cyanine Link Between Propargylamine Drugs and Monoamine Oxidase Clarifies the Inactivation Mechanism. *Frontiers in Chemistry*, **2018**, 6, 169	5	18
20	Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches. *MedChemComm*, **2019**, 10, 10-25	5	22
19	Computational Insight into the Mechanism of the Irreversible Inhibition of Monoamine Oxidase Enzymes by the Antiparkinsonian Propargylamine Inhibitors Rasagiline and Selegiline. *ACS Chemical Neuroscience*, **2019**, 10, 3532-3542	5.7	27
18	A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review. *European Journal of Medicinal Chemistry*, **2020**, 206, 112787	6.8	55
17	Click-Reaction-Triggered SERS Signals for Specific Detection of Monoamine Oxidase B Activity. *Analytical Chemistry*, **2020**, 92, 15050-15058	7.8	7
16	Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
15	TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology. *Journal of Pharmacy and Pharmacology*, **2020**, 72, 1001-1012	4.8	29
14	Molecular docking utilising the OliveNet□library reveals novel phenolic compounds which may potentially target key proteins associated with major depressive disorder. *Computational Biology and Chemistry*, **2020**, 86, 107234	3.6	2
13	The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase. *Molecular Diversity*, **2021**, 25, 491-507	3.1	3
12	An Update of Synthetic Approaches and Structure-Activity Relationships of Various Classes of Human MAO-B Inhibitors. *ChemistrySelect*, **2021**, 6, 1404-1429	1.8	3

11	Questions in the Chemical Enzymology of MAO. *Chemistry*, **2021**, 3, 959-978	2.1	2
10	Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer's disease. *Bioorganic Chemistry*, **2021**, 114, 105070	5.1	5
9	Synthesis of Chiral Helic[1]triptycene[3]arenes and Their Enantioselective Recognition Towards Chiral Guests Containing Aminoindan Groups. *Molecules*, **2021**, 26,	4.8	3
8	Multitarget Biological Profiling of New Naphthoquinone and Anthraquinone-Based Derivatives for the Treatment of Alzheimer's Disease. *ACS Chemical Neuroscience*, **2021**, 12, 447-461	5.7	9
7	Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer's Disease. *Current Pharmaceutical Design*, **2020**, 26, 4690-4698	3.3	15
6	First Synthesis of Racemic Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer's Disease. *Molecules*, **2020**, 26,	4.8	5
5	Indoles and 1-(3-(benzyloxy)benzyl)piperazines: Reversible and selective monoamine oxidase B inhibitors identified by screening an in-house compound library.. *Bioorganic Chemistry*, **2021**, 119, 105581	5.1	0
4	The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.. *Bioorganic and Medicinal Chemistry Letters*, **2022**, 67, 128746	2.9	0
3	Data_Sheet_1.docx. **2018**,		
2	Computational Chemistry and Molecular Modeling of Reversible MAO Inhibitors. **2023**, 221-252		0
1	MAO Visible Spectroscopy for Ligand Interactions, Redox Chemistry, and Kinetics of Irreversible Inhibition. **2023**, 63-74		0